Incidence, source, and prognostic impact of major bleeding across the spectrum of aortic stenosis.


Journal

American heart journal
ISSN: 1097-6744
Titre abrégé: Am Heart J
Pays: United States
ID NLM: 0370465

Informations de publication

Date de publication:
08 2023
Historique:
received: 17 01 2023
revised: 30 03 2023
accepted: 07 04 2023
medline: 16 6 2023
pubmed: 27 4 2023
entrez: 26 4 2023
Statut: ppublish

Résumé

Severe aortic stenosis (AS) has been associated with bleeding. However, there is a lack of prospective assessment of bleeding events and their clinical significance in a large population of outpatients with variable degree of AS severity. To assess the incidence, source, determinants, and prognostic impact of major bleeding in patients with variable degree of AS severity. Between May 2016 and December 2017, consecutive outpatients were included. Major bleeding was defined as type ≥3 bleed using the Bleeding Academic Research Consortium definition. Cumulative incidence was calculated with death as the competing event. Data was censored at time of aortic valve replacement. Among 2,830 patients, 46 major bleeding events occurred (0.7%/year) during a median follow-up of 2.1 years (interquartile range: 1.4-2.7). Most frequent sites of bleeding were gastrointestinal (50%) and intracranial (30.4%). Major bleeding was significantly associated with all-cause mortality (hazard ratio: 5.93 (95% confidence interval 3.64-9.65); P < .001). AS severity was associated with major bleedings (P = .041). By multivariable analysis, severe AS was an independent determinant of major bleeding (hazard ratio vs mild AS: 3.59 [95% confidence interval 1.56-8.29]; P = .003). The increased risk of bleeding associated with severe AS was significantly exacerbated in patients using oral anticoagulation. In AS patients, major bleeding is rare but a strong independent predictor of death. AS severity is a determinant of bleeding events. Severe AS and oral anticoagulation should be identified as an association at very high risk of major bleeding.

Sections du résumé

BACKGROUND
Severe aortic stenosis (AS) has been associated with bleeding. However, there is a lack of prospective assessment of bleeding events and their clinical significance in a large population of outpatients with variable degree of AS severity.
OBJECTIVES
To assess the incidence, source, determinants, and prognostic impact of major bleeding in patients with variable degree of AS severity.
METHODS
Between May 2016 and December 2017, consecutive outpatients were included. Major bleeding was defined as type ≥3 bleed using the Bleeding Academic Research Consortium definition. Cumulative incidence was calculated with death as the competing event. Data was censored at time of aortic valve replacement.
RESULTS
Among 2,830 patients, 46 major bleeding events occurred (0.7%/year) during a median follow-up of 2.1 years (interquartile range: 1.4-2.7). Most frequent sites of bleeding were gastrointestinal (50%) and intracranial (30.4%). Major bleeding was significantly associated with all-cause mortality (hazard ratio: 5.93 (95% confidence interval 3.64-9.65); P < .001). AS severity was associated with major bleedings (P = .041). By multivariable analysis, severe AS was an independent determinant of major bleeding (hazard ratio vs mild AS: 3.59 [95% confidence interval 1.56-8.29]; P = .003). The increased risk of bleeding associated with severe AS was significantly exacerbated in patients using oral anticoagulation.
CONCLUSION
In AS patients, major bleeding is rare but a strong independent predictor of death. AS severity is a determinant of bleeding events. Severe AS and oral anticoagulation should be identified as an association at very high risk of major bleeding.

Identifiants

pubmed: 37100186
pii: S0002-8703(23)00099-6
doi: 10.1016/j.ahj.2023.04.011
pii:
doi:

Substances chimiques

Anticoagulants 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

140-147

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Disclosures None reported.

Auteurs

Augustin Coisne (A)

Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, Lille, France; Cardiovascular Research Foundation, New York, NY. Electronic address: augustin.coisne@chu-lille.fr.

Samy Aghezzaf (S)

Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, Lille, France.

Laura Butruille (L)

Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, Lille, France.

Eloise Woitrain (E)

Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, Lille, France.

Sandro Ninni (S)

Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, Lille, France.

Francis Juthier (F)

Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, Lille, France.

Arnaud Sudre (A)

Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, Lille, France.

André Vincentelli (A)

Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, Lille, France.

Nicolas Lamblin (N)

Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, Lille, France.

Gilles Lemesle (G)

Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, Lille, France; Heart and Lung Institute, University hospital of Lille, Lille, France; FACT (French Alliance for Cardiovascular Trials), Paris, France.

David Montaigne (D)

Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, Lille, France.

Christophe Bauters (C)

Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, Lille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH